CY1120767T1 - GLP-1 PEPTYE COMPOSITIONS AND THEIR PREPARATION - Google Patents

GLP-1 PEPTYE COMPOSITIONS AND THEIR PREPARATION

Info

Publication number
CY1120767T1
CY1120767T1 CY181101043T CY181101043T CY1120767T1 CY 1120767 T1 CY1120767 T1 CY 1120767T1 CY 181101043 T CY181101043 T CY 181101043T CY 181101043 T CY181101043 T CY 181101043T CY 1120767 T1 CY1120767 T1 CY 1120767T1
Authority
CY
Cyprus
Prior art keywords
glp
granules
compositions
peptye
preparation
Prior art date
Application number
CY181101043T
Other languages
Greek (el)
Inventor
Thomas Vilhelmsen
Helle Eliasen
Tue Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/055362 external-priority patent/WO2013139694A1/en
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CY1120767T1 publication Critical patent/CY1120767T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά φαρμακευτικές συνθέσεις που περιλαμβάνουν έναν πρώτο τύπο κόκκων και έναν δεύτερο τύπο κόκκων, όπου ο εν λόγω πρώτος τύπος κόκκων περιλαμβάνει ένα άλας του Ν-(8-(2-υδροξυβενζοϋλ)αμινο)καπρυλικού οξέος και όχι GLP-1 πεπτίδιο, και όπου ο εν λόγω δεύτερος τύπος κόκκων περιλαμβάνει ένα GLP-1 πεπτίδιο και όχι άλας του Ν-(8-(2-υδροξυβενζοϋλ)αμινο)καπρυλικού οξέος, όπως επίσης τους ενδιάμεσους κόκκους, μεθόδους για την παρασκευή των κόκκων και συνθέσεις και χρήση αυτών στην ιατρική.The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises an N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt and not a GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and not a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid, as well as intermediate granules, methods for preparing granules and compositions and using them in medicine.

CY181101043T 2012-03-22 2018-10-10 GLP-1 PEPTYE COMPOSITIONS AND THEIR PREPARATION CY1120767T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12160743 2012-03-22
US201361748840P 2013-01-04 2013-01-04
EP13153459 2013-01-31
PCT/EP2013/055362 WO2013139694A1 (en) 2012-03-22 2013-03-15 Compositions of glp-1 peptides and preparation thereof
EP13709231.8A EP2827885B1 (en) 2012-03-22 2013-03-15 Compositions of glp-1 peptides and preparation thereof

Publications (1)

Publication Number Publication Date
CY1120767T1 true CY1120767T1 (en) 2019-12-11

Family

ID=65910839

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101043T CY1120767T1 (en) 2012-03-22 2018-10-10 GLP-1 PEPTYE COMPOSITIONS AND THEIR PREPARATION

Country Status (4)

Country Link
KR (1) KR102266299B1 (en)
CY (1) CY1120767T1 (en)
IL (1) IL234228B (en)
PT (1) PT2827885T (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2656019C (en) * 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
AU2009283821B2 (en) * 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
BR112012028136A2 (en) * 2010-05-05 2016-08-09 Boehringer Ingelheim Int combination therapy
MY171146A (en) * 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof

Also Published As

Publication number Publication date
PT2827885T (en) 2018-11-05
KR102266299B1 (en) 2021-06-18
IL234228B (en) 2019-03-31
KR20200013078A (en) 2020-02-05

Similar Documents

Publication Publication Date Title
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
CY1120805T1 (en) CRYSTAL FORMS SUSPENDER HYDROXYLASION PROYLO
CY1121225T1 (en) CONCENTRATED IMIDAZOLYLIMIDAZOLS AS ANTIQUES
CY1119058T1 (en) IMIDAZOPYRROLIDINONE COMPOUNDS
CY1120730T1 (en) ORAL DOSAGE OF GLP-1 COMPOUNDS
EA201890123A1 (en) NEW AMINO ACID DERIVATIVES, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA201891099A1 (en) 7- (TIAZOL-5-IL) Pyrrolopyrimide as an agonist of the TLR7 receptor
CY1121736T1 (en) ARAMCHOL SALTS
EA201992133A1 (en) PIPERIDINO-PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS
CY1122483T1 (en) MELPHALAN FLUFENAMIDE LYOPHYDRIED PRECAUTIONS
EA201401292A2 (en) NEW THYENOPYRIMIDINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA201391719A1 (en) HINASOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
EA201591166A1 (en) AUTOTAXIN INHIBITORS
MX2013013913A (en) Polypeptides.
EA201590343A1 (en) ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
EA201590667A1 (en) ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
EA201690246A1 (en) AUTOTOXIN INHIBITORS CONTAINING A NUCLEAR HETEROAROMATIC RING-BENZYL-AMIDE CYCLE
EA201591751A1 (en) TRIPEPTIDE EPOKEKETONE PROTEASE INHIBITORS
CY1121881T1 (en) PHARMACEUTICAL FORM CONTAINING FIXED RATIO INSULIN GLARGINE/LIXISENATIDE
BR112015001327A2 (en) 1-cyano-2- (4-cyclopropyl-benzyl) -4- (beta-d-glycopyran-1-yl) -benzene crystalline complex, methods for its preparation and use thereof to prepare medicaments
EA201791600A1 (en) DERIVATIVES OF HYDROXIALKILPIPERASINE AS RECESSOR CXCR3 MODULATORS
BR112017013574A2 (en) amino acid and peptide conjugates and uses thereof
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
MX2014004953A (en) Tyrosine based linkers for the releasable connection of peptides.
EA201690390A1 (en) AMIDO DERIVATIVES AS ANTAGONISTS OF A RECEPTOR FOR LYSOPHOSPHATIDIC ACID